◆ SpookStack

FD-302a (Rev. 10-6-95) 279A-WF-222936-USAMRIID iter fermentor) as two fermentors also i w Brunswick, stock # las having Bio Flow III, 3- liter fermentor, been moved £rom Inventory sheet shown to section of the file. During significant segments of the interview, [—__] asserted that the Anthrax investigation was not focused in the right direction; that the investigative spotlight should be much broader and that investigative efforts should focus more on the human/financial motivational aspects of the crime as opposed to the scientific angle. suggested that investigative efforts should be more focused on a company called Bioport and not USAMRIID. indicated that the investigation has greatly interfered with USAMRIID's work and that a closer scrutiny of Bioport would reveal that Bioport is the one entity that has financially benefitted the most from the anthrax mailings. USAMRIID has not benefitted from the anthrax mailings but in retrospect has suffered. [_] explained that since the anthrax mailings and the subsequent investigation at USAMRIID, funding has significantly been cut, projects have fallen behind schedule, and the implementation of control and ability measures has been restrictive and time consuming. explained that it currently takes approximately 12 years and $800 million dollars to develop a new biological product and that the anthrax mailings, in opinion, have caused a two year delay. According to[______]prior to the anthrax mailings, Bioport's anthrax vaccine program had been cited for 14 violations by the Food and Drug Administration (FDA), also known as 483 violations, resulting in Bioport having to stop production and sale of the vaccine. During this same time period, USAMRIID had already been working on a new anthrax vaccine which was ready for clinical testing. USAMRIID was directed to go to Bioport and attempt to resolve the deficiencies that existed with_the old anthrax vaccine ogram. USAMRIID employees BRUCE IVINS, Lvere tasked with this effort. Bioport needed to improve its employee training program, update their facilities, and validate their efficacy models. Ultimately, as a result of the anthrax mailings, Bioport's anthrax vaccine was re-licensed. asserted that Bioport was ultimately successful in delaying the development and sale of the new USAMRIID anthrax vaccine while